CPI-0610, a bromodomain and extraterminal domain (BET) protein inhibitor, in combination with ruxolitinib, in JAK-inhibitor-naïve myelofibrosis patients: Update of MANIFEST phase 2 study Meeting Abstract
| Authors: | Platzbecker, U.; Mascarenhas, J.; Harrison, C.; Patriarca, A.; Devos, T.; Palandri, F.; Rampal, R.; Vannucchi, A.; Mead, A.; Kremyanskaya, M.; Somervaille, T.; Wondergem, M.; Hoffman, R.; Luptakova, K.; Wang, J.; Colak, G.; Shao, J.; Bobba, S.; Trojer, P.; Verstovsek, S.; Gupta, V. |
| Abstract Title: | CPI-0610, a bromodomain and extraterminal domain (BET) protein inhibitor, in combination with ruxolitinib, in JAK-inhibitor-naïve myelofibrosis patients: Update of MANIFEST phase 2 study |
| Meeting Title: | Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie (Hybrid-Kongress) |
| Journal Title: | Oncology Research and Treatment |
| Volume: | 44 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2021 Oct 01-04 |
| Meeting Location: | Berlin, Germany |
| ISSN: | 2296-5270 |
| Publisher: | S. Karger AG |
| Date Published: | 2021-09-01 |
| Start Page: | 158 |
| Language: | English |
| ACCESSION: | WOS:000760622600290 |
| PROVIDER: | wos |
| DOI: | 10.1159/000518417 |
| Notes: | Meeting Abstract: ep308-- Meeting was also presented virtually -- "Joint Annual Meeting of the German, Austrian and Swiss Societies for Hematology and Medical Oncology (Hybrid Congress)" -- Source: Wos |
